Mice were infected, after corneal scarification, with 106 to 107 PFU of HSV-1(F) per eye (26, 27) . At 4 weeks postinoculation, infectious virus was no longer detectable in the central nervous system and peripheral nervous system but could be reactivated after explant cultivation of the trigeminal ganglia ( Fig. 1 and Table 1 ). Infectious virus was first detectable at 2 days postexplant, and by 4 days postexplant virus could be recovered from all of the ganglia (Fig. 1) . The effect on reactivation was assayed by adding the topoisomerase inhibitors to ganglia at explant. The appearance of reactivated HSV-1 was completely inhibited by novobiocin (160 ,uM) and coumermycin A1 (9 FiM) at 4 days (Table 1 ) or 8 days (data not shown) postexplant. The effects of novobiocin and coumermycin A1 on HSV-1 reactivation were reversible. When novobiocin (160 ,uM) or coumermycin A1 (9 ,uM) was added at explant and removed at day 4, reactivation occurred in all of the ganglia by day 8. When two other topoisomerase inhibitors, nalidixic acid and oxolinic acid, were used, reactivation occurred in 100% of the ganglia (Table 1) .
Concentrations of novobiocin and coumermycin Al that inhibited reactivation were weak inhibitors of HSV-1 replication in permissive cells (CV-1) infected at a multiplicity of infection of 1 PFU per cell (Table 2) or 0.01 PFU per cell (data not shown). Nalidixic acid and oxolipic acid were also weak inhibitors of HSV-1 replication in CV-1 cells (Table 2) , consistent with results obtained by using BHK cells (9) . * Corresponding author.
Since a compound with antiviral activity might indirectly affect reactivation, phosphonoacetic acid, an inhibitor of HSV-1 replication (24) , and its encoded DNA polymerase (18) were studied. At concentrations that exhibited the maximum antiviral activity in CV-1 cells (Table 2 ), 1.4 to 2,9 mM (200 to 400 ,ug/ml), phosphonoacetic acid affected HSV-1 reactivation (Table 1) . Thus, any effect of phosphonoacetic acid on reactivation could not be distinguished from its antiviral activity.
Although novobiocin and coumermycin A1 did not exhibit potent antiviral activity in CV-1 cells, their effects in C1300 cells (Table 2 ), a neuroblastoma cell line (20) , and in acutely infected ganglia (Table 3 ) were significant. Nalidixic acid and oxolinic acid were not more potent in C1300 cells than in CV-1 cells ( Table 2) . The difference in antiviral activity of novobiocin in CV-1 and C1300 cells was not due to a difference in cytotoxicity, since novobiocin (160 ,uM) increased the doubling times of both cell lines from about 24 h to 48 h (data not shown). Because novobiocin and coumermycin A1 inhibited HSV-1 replication in cells of neuronal origin and in acutely infected ganglia to a greater extent than they did in CV-1 or BHK (9) cells, the antiviral activity may be the result of an effect on the host cell or on a viral function required only in some cell types. This antiviral activity may account for the effects of novobiocin and coumermycin A1 on HSV-1 reactivation.
To determine whether the inhibitors had an effect on the structure of the latent genome and the synthesis of viral DNA, DNA was extracted from ganglia (27) that had been incubated for 4 days in explant culture. Latent HSV-1 DNA lacks free termini and can be distinguished from linear virion DNA by BamHI digestion and Southern blot analysis (7, 26, 27) . In the presence of novobiocin or coumermycin A1 the terminal BamHI fragments, P and S, were not detectable and the amount of HSV-1 DNA did not increase greatly relative to the latent sample (Fig. 2, lanes 1 to 3) . In the reactivated sample the amount of HSV-1 DNA increased 1,000-fold, and BamHI fragments P and S were present (Fig. 2, lane 4) .
In explanted ganglia exposed to novobiocin (160 ,uM) for 3 days and labeled overnight, the incorporation of thymidine into acid-precipitable macromolecules was inhibited by about 95 + 4% (data not shown), consistent with an effect on DNA synthesis. Novobiocin had a less inhibitory effect on the incorporation of uridine and amino acids (30 and 40%, "Compounds were present continuously from 1 h prior to infection until the cultures were freeze-thawed at 20 to 24 h postinfection and until titers were determined (28) . PAA, Phosphonoacetic acid. respectively). Phosphonoacetic acid (1.4 mM) did not inhibit the incorporation of any precursor significantly (data not shown), as previously reported (24) . UV light can stimulate the reactivation of latent HSV-1 (3, 6, 11) , and repair DNA synthesis stimulated by UV-induced DNA damage is sensitive to novobiocin (4, 19) . These results and those described above (Fig. 2) suggest that the inhibition of reactivation was due to an effect on one or more events involved in, or prior to, HSV-1 DNA synthesis.
Novobiocin and coumermycin Al may affect the ability of C1300 cells or cells in ganglia to express cellular functions required for HSV-1 permissiveness or may affect viral functions necessary for latent HSV-1 to reenter the replication cycle. The induction of early viral antigens in cells latently infected with Epstein-Barr virus, after a reactivation stimulus, can be blocked reversibly by novobiocin and coumermycin A1 (12) . Other possible explanations for the inhibition by novobiocin and coumermycin A1 of HSV-1 replication in ganglia and C1300 cells but not in CV-1 cells include differences in the cellular topoisomerases present, drug uptake, or metabolism.
Topoisomerase activities have been found in many cell types (5, 10, 30, 31) and are induced in vaccinia virus (1, 8) and HSV-1-infected cells (2, 16, 21) . The sensitivity of the HSV-1-induced topoisomerase activity to inhibitors is not known, but a vaccinia virus-encoded enzyme is inhibited 50% by 180 p.M novobiocin (8) . Drosophtila topoisomerase type II is inhibited by novobiocin and coumermycin A1, with Kis of 210 and 10 F.M, respectively (22) . These levels are similar to those that inhibited HSV-1 reactivation (Table 1) (26, 27) . Kodak XAR film was exposed for 3 days. The positions of the BamHI restriction fragments PS, P, and S are labeled.
of novobiocin and coumermycin A1 on the virus or on the host cell. Indeed, it should be emphasized that the possibility that they inhibit reactivation and replication in trigeminal ganglia through a mechanism other than an effect on a DNA topoisomerase of cellular or viral origin cannot be ruled out. However, the reactivation system presented in this manuscript may be of value to identify the critical events during the reactivation of latent HSV-1, to study the effect of inhibitors, and to analyze HSV-1 mutants.
Cloned BamHl fragment PS (25) was a generous gift of B. Roizman, University of Chicago. C1300 (clone NA) (20) 
